SS-31 (Elamipretide)

SS-31 (H-D-Arg-Dmt-Lys-Phe-NH₂, where Dmt is 2,6-dimethyl-L-tyrosine) is a synthetic aromatic-cationic tetrapeptide from the Szeto-Schiller series that selectively accumulates in the inner mitochondrial membrane. Its targeting is driven by electrostatic attraction between its cationic residues (D-Arg, Lys) and the negatively charged cardiolipin phospholipid, combined with hydrophobic insertion into the lipid bilayer. Cardiolipin is almost exclusively found in the inner mitochondrial membrane and is essential for cristae architecture, electron transport chain (ETC) supercomplex assembly, and cytochrome c function.

The primary mechanism is cardiolipin protection and stabilization. Under oxidative stress, cytochrome c dissociates from cardiolipin and converts into a peroxidase that peroxidizes cardiolipin, disrupting ETC supercomplexes, collapsing cristae structure, and unleashing a vicious cycle of electron leak and ROS production. SS-31 binds cardiolipin and prevents this cytochrome c conformational shift, preserving its electron-carrier function while inhibiting its pathological peroxidase activity. This is fundamentally different from direct antioxidant mechanisms — SS-31 reduces mitochondrial ROS indirectly by improving electron transport efficiency and reducing electron leak, rather than by scavenging free radicals.

Downstream effects include: preservation of cristae morphology after ischemic or metabolic stress; enhanced assembly and stability of ETC complexes I–IV and their supercomplexes; restored oxygen consumption and ATP synthesis efficiency; and modulation of cardiolipin-dependent membrane surface electrostatics that tunes how proteins associate with the membrane. The use of D-amino acids (D-Arg, Dmt) confers resistance to proteolytic degradation.

SS-31 (elamipretide, formerly MTP-131/Bendavia) was developed by Drs. Hazel Szeto and Peter Schiller at Cornell University in the early 2000s as part of a systematic search for mitochondria-targeted peptides. Stealth BioTherapeutics advanced the compound through an extensive clinical program spanning heart failure (PROGRESS-HF), primary mitochondrial myopathy (MMPOWER-3), Barth syndrome (TAZPOWER), and dry age-related macular degeneration (ReCLAIM-2).

The clinical history has been mixed: PROGRESS-HF, MMPOWER-3, the randomized portion of TAZPOWER, and ReCLAIM-2 all failed to meet their primary endpoints. However, on September 19, 2025, the FDA granted accelerated approval to elamipretide hydrochloride (Forzinity) for improving muscle strength in Barth syndrome patients — the first approved therapy for this rare mitochondrial disorder and the first FDA-approved cardiolipin-directed agent. Continued approval may be contingent on confirmatory trial results. A 2021 mechanistic study in older adults demonstrated that a single IV infusion improved in vivo skeletal muscle mitochondrial ATP production, reversing age-related declines — one of the strongest human bioenergetic signals for any mitochondrial-targeted compound.

Store lyophilized SS-31 at -20°C in a light-protected, desiccated container. The peptide's D-amino acid residues (D-Arg, Dmt) confer significant resistance to standard peptidases. Stability data is well-characterized from the pharmaceutical development program; lyophilized material is stable >24 months at -20°C.

After reconstitution with bacteriostatic water, SS-31 should be refrigerated at 2–8°C and used within 21 days. The peptide is water-soluble and forms a clear, colorless solution. Do not freeze reconstituted solutions. For research protocols using larger doses (20–40 mg), reconstitute at higher concentrations (e.g., 1.0 ml BAC water for 10mg = 10 mg/ml) to manage injection volume. SS-31 has been researched both as monotherapy and in combination with MOTS-c for complementary mitochondrial effects — SS-31 targeting membrane structure/cardiolipin and MOTS-c targeting nuclear-mitochondrial crosstalk via AMPK/SIRT1.